LATE BREAKER
Preliminary results of a phase II, randomized, open-label, active-treatment controlled trial of rhGH and rhIGF-1 combination therapy in prepubertal children with non-severe primary IGF-1 deficiency
Preliminary results of a phase II, randomized, open-label, active-treatment controlled trial of rhGH and rhIGF-1 combination therapy in prepubertal children with non-severe primary IGF-1 deficiency
L Kurt Midyett, Barry Reiner, Alan D Rogol, Mitchell E Geffner, James W Frane, George M Bright
Clinical Trial Review from the LWPES/ESPE meeting
Jay Cohen, MD and Barry Reiner, MD review the preliminary results of a phase II, randomized, open-label, active-treatment controlled trial of rhGH and rhIGF-1 combination therapy in prepubertal children with non-severe primary IGF-1 deficiency.
Effects of Growth Hormone and Nutritional Therapy in Boys with Constitutional Growth Delay: A Randomized Controlled Trial
Joan Han, Ligeia Damaso, Susan Welch, Shawn Sweeten, Prabhakaran Balagopal, Nelly Mauras
ISS – Evaluating Growth Response from Clinical Trials in the KIGS database
Kerstin Albertsson-Wikland, Berit Kriström, Anders Lindberg
The Relationship Between IGF-1 Response and 1st year Height Velocity on two different doses of GH in Idiopathic GH Deficiency (IGHD) : A randomized, Prospective Multicentre Clinical Study
Ruveyde Bundak,İlknur Arslanoğlu, Merih Berberoğlu, et al.
Evaluation of the Prediction model used in a randomized individualized GH dose study in short GHD and ISS children, with addition of KIGS SGA dose module
Kerstin Albertsson-Wikland, Berit Kriström, Andreas FM Nierop
Expert Comentary: Clinical Trial Update
First-Year Height Velocities with Once-Daily and Twice-Daily Dosing of rhIGF-1 in Prepubertal Children with Primary IGF-1 Deficiency
First-Year Height Velocities with Once-Daily and Twice-Daily Dosing of rhIGF-1 in Prepubertal Children with Primary IGF-1 Deficiency
Kurt Midyett, MD
Alan Rogol, MD
Alan Rogol, MD
Prediction model for individualized GH dosing
Kerstin Albertsson-Wikland, Berit Kriström, Jovanna Dahlgren, Aimon Niklasson, Andreas FM Nierop
Analysis of the effect of IGF1 (CA)n repeats on the growth response to rhGH therapy in patients with severe growth hormone deficiency
Everlayny Fiorot Costalonga, Sonir Roberto R Antonini, Gil Guerra-Junior,et al.
Long-term efficacy of growth hormone (GH) therapy in prepubertal children with GH deficiency: results of a randomized dose response 4-year trial
Pinchas Cohen, Wayne Weng, Alan Rogol, Ron Rosenfeld, Anne-Marie Kappelgaard, and John Germak
Two-years GH therapy with intermittent discontinuation: a cost effective therapy in SGA
Amir Hadash, Zvi Zadik, Tomas Ngwiri, and Ze’ev Hochberg, Dov Tiosano
Final height of growth hormone deficient patients treated before one year of age: a therapeutic model
Candace Ben signor, Jean-Claude Carel, Michel Polak, Jean Vital De Monléon, Jean-Louis Chaussain, Frédéric Huet
Isolated GHD vs Hypopituitarism: Phenotype and Response
F Darendeliler, A Lindberg, P Wilton
Prader-Willi syndrome: long-term continuous growth hormone treatment and the cardiovascular and metabolic risk profile of young children
Roderick F A de Lind van Wijngaarden, Elbrich P C Siemensma, Dederieke A M Festen, Barto J Otten, Anita C S Hokken- Koelega
Psychosocial Health and Levels of Employment in 851 GH Deficient Swedish Patients on Complete Hormone Replacement Including GH
Eva-Marie Erfurth, MD
Endocrine Actions of Myostatin; Systemic Regulation of the Insulin-Like Growth Factor (IGF) and IGF Binding Protein Axis
Dan Rodgers, MD
Expert Commentary: Review of Treatments for Short Stature
Mitchell Geffner, MD
Kurt Midyett, MD
Kurt Midyett, MD
Normal Final Height after Late Growth Hormone Treatment of Patients with Growth Hormone Deficiency
Ivo Arnhold, MD
Six Months Efficacy and Safety of a Novel Once-a-Week Sustained Release RhGH (LB03002) in Adults with GHD; A Phase III, Double-Blind Placebo-Controlled Study
Beverly M.K. Biller, MD
Genetic Polymorphisms Associated with Changes in Serum IGF-I in Prepubertal Children with Growth Hormone Deficiency (GHD) or Turner Syndrome (TS) after One Month of Growth Hormone (GH) Therapy: The PREDICT Study Introducing Pharmacogenomics into Clini
PE Clayton, P Chatelain, V Peterkova, A Belgorosky, D Veimo, A Ferrandez, M Tuefferd, J Dauvillier, L Tato, and PREDICT Investigators
Four Year Efficacy and Safety Data of Treatment with Omnitrope® 5 mg/ml Lyophilized Formulation in Children with Growth Failure Due to Growth Hormone Deficiency
F Peter, T Romer, B Koehler, E Solyom, M Walczak, A Muzsnai, A Rudzka-Kocjan, E Kaluza-Guzikowska, E Petriczko, and PH Saenger
Serum IGF-1 Increment after a Month of Growth Hormone Treatment is Effective for Prediction of Growth Response in Idiopathic Short Stature
HW Chae, EB Lee, HS Kim, and DH Kim
Reduced Injection Dose Force Dynamics of Next Generation Norditropin NordiFlex® Compared to Current Norditropin NordiFlex® Pen Device
N-AB Hansen, M Vang-Petersen, L Hourman Ditlefsen, and A-M Kappelgaard
Hypothyroidism in Pediatric Patients Treated with Recombinant Human Growth Hormone
KN Wong, LL Levitsky, and M Misra
The Growth Hormone-IGF-1 Axis after Bone Marrow Transplantation (BMT) with Total Body Irradiation (TBI) in Childhood: Qualitative and Quantitative Abnormalities and Impact of Adiposity
NL Davis, R Elson, CE Stewart, A Moss, W Woltersdorf, JM Cornish, MCG Stevens, and EC Crowne
Growth Response to Individualized vs. Fixed Dose Growth Hormone (GH) Treatment in Short Children Born Small for Gestational Age (SGA): Two-Year Results of the OPTIMA Trial
H Jung, C Land, WF Blum, C Nicolay, and E Schonau
Effects of Doubled GH Dose on Growth Parameters in Early Pubertal GHD Patients
Giuseppe Saggese, MD
Method To Estimate Mean Serum IGF-1 Concentration during rhIGF-1 Treatment Using a Single Blood Sample
GM Bright, S Liao, and JW Frane
Craniofacial and Extremity Growth Evaluation in Patients with Turner Syndrome during Growth Hormone Therapy
Maria Estela Justamante de Faria, MD
Growth Hormone Administration Reduces Visceral Adiposity and HsCRP in Patients with Growth Hormone Deficiency Following Cure of Acromegaly: A Randomized, Placebo-Controlled Study
Karen K. Miller, MD